Blog
Best AI Stock for 2024: Palantir Stock vs. Nvidia Stock
Fool.com contributor Parkev Tatevosian compares Palantir (NYSE: PLTR) and Nvidia (NASDAQ: NVDA) across a number of financial metrics to determine which is the better AI stock to buy.
*Stock prices
3 Top Trends to Invest $100 in Right Now
The global economy stands at a unique crossroads at the end of 2023. The coronavirus health crisis is no longer an active pandemic, but its aftershocks will continue to reshape the world for years
Why Triumph Group Stock Is Soaring to the Clouds Today
Triumph Group (NYSE: TGI) has agreed to sell its product support business for $725 million, cash that will immediately boost the struggling aerospace company's balance sheet. Investors are excited
This Growth Stock Could 10x in 10 Years
Roku (NASDAQ: ROKU) is a market leader in an expanding industry, but this doesn't mean that the shares can pop tenfold in the next 10 years. The starting line is kind right now. Roku may have more
Is the Vanguard Information Technology Index Fund the Best Tech ETF?
Technology has been a dominant force in the stock market for the last two decades. Some of the world's most valuable companies, such as Nvidia, Meta Platforms, and Advanced Micro Devices, belong to
In 2024, Social Security Will Be Just a Decade Away From Disaster
As of November 2023, over 52.6 million people receive monthly retirement-related benefits from Social Security, and the program pays out nearly $95 billion in retirement benefits each month. That's
Down 66%, Is This Growth Stock a Buy Going Into 2024?
In this video, I will talk about Coupang (NYSE: CPNG), the current state of the company, the "acquisition" of Farfetch, and why I believe this stock has been flying under the radar while the
Better Growth Stock: AbbVie vs. Abbott Laboratories
Drugmaker AbbVie (NYSE: ABBV) spun off from Abbott Laboratories (NYSE: ABT) at the start of 2013. The growth-oriented pharma business has become a beast, generating more than $58 billion in revenue
Where Will Walgreens Boots Alliance Be in 1 Year?
Walgreens Boots Alliance (NASDAQ: WBA) stock has crashed by 32% year to date. After an abysmal year, it's not just hitting new 52-week lows -- it's hitting lows it hasn't seen since 2009.
The road
The Top Healthcare Stocks to Buy With $100
How much money does one need to start investing in stocks? $1 million? $10,000? The truth is, even a relatively modest sum of $100 is enough to get started for two reasons. First, nowadays, it isn't
Half of Warren Buffett's $313 Billion Berkshire Hathaway Portfolio is Invested in This 1 Stock. Here's Why He's Not Too Concerned About Concentration Risk.
As CEO of Berkshire Hathaway, Warren Buffett has one of the most impressive investing track records on Wall Street. Since taking over the top position at Berkshire in 1965 through 2022, he and his
3 Growth Stocks to Buy That Could Be Massive Long-Term Winners
A tried and tested way of making money in the stock market is buying and holding solid companies for the long run. This strategy allows investors to capitalize on secular growth trends and helps
Weighing Their Chances: 5 Leading Healthcare Companies Fight for Market Share in the $100 Billion Weight-Loss Industry
The anti-obesity drug market could be worth $100 billion by 2030, according to analysts from Goldman Sachs. It's a mammoth market and one that looks to be heating up with a growing number of large
Is Devon Energy the Best Dividend Stock for You?
Devon Energy (NYSE: DVN) has a very attractive dividend yield at 6.4%. That compares favorably to energy industry giants like ExxonMobil, which has a yield of just 3.7%. The average energy stock
How AMD's Stock Price Can Continue to Grow in 2024
In today's video, I discuss recent updates affecting Advanced Micro Devices (NASDAQ: AMD). Check out the short video to learn more, consider subscribing, and click the special offer link below.
Down 20% in 2023, Is Beyond Meat Stock a Buy Now?
Beyond Meat (NASDAQ: BYND) investors had a forgettable 2023. Shares of the plant-based meat specialist declined 20% through mid-December even as the broader market rallied. The beaten-down stock is
Looking to Invest in the Next Big Craze Like Ozempic? This 1 Emerging Field Could Be It.
Novo Nordisk's (NYSE: NVO) Ozempic is so popular that it's practically self-marketing. For shareholders, that popularity has translated into achieving a total return of 48% over the past 12 months
Warren Buffett Just Added $589 Million to 1 of Berkshire Hathaway's Top Holdings
Warren Buffett hasn't seen a lot to like in the stock market in 2023, but there's one stock he keeps buying.
The Oracle of Omaha has been a net seller of stocks through the first nine months of the
Is AT&T a Better Income Vehicle Than This High-Yield Vanguard Dividend ETF?
Investing in stocks requires careful analysis of the potential risks and returns. One way to evaluate a stock is to consider how it fits into your portfolio. For example, do you want a stock that
C3.ai's Struggles Continue. Is the Stock in Trouble or a Bargain Buy?
C3.ai (NYSE: AI) is a pure-play artificial intelligence (AI) business. It helps provide AI solutions to companies in various industries, which suggests it should benefit from more businesses showing
This Growth Stock Has Market-Beating Potential
Investors are starting to look for promising stocks that can beat major indexes over the next bull market. If the Fed cuts interest rates ahead of Wall Street's expectations, risk tolerance will
2 Reasons Amazon Is a Dynamite Stock for 2024
There were a lot of questions swirling around Amazon (NASDAQ: AMZN) stock at the beginning of this year. Amazon Web Services' (AWS) growth rate slowed from 27% in 2021 to 12% in the third quarter of
Are the "Magnificent Seven" Stocks Too Risky for You? Consider This Fund
Investing in the S&P 500 is normally a sound long-term strategy. But this year, while its valuation has been rising 23%, that has largely been due to seven stocks. Known as the "Magnificent Seven,"
6 Words That Explain Why CRISPR Stock Isn't Soaring Despite the Recent FDA Approval for Its Gene-Editing Therapy
December has been a big month for CRISPR Therapeutics (NASDAQ: CRSP). On Dec. 8, the Food and Drug Administration (FDA) granted approval for CRISPR's gene-editing therapy, Casgevy, as a treatment
This Indicator Has Predicted Every Bear Market for 40 Years and Could Hint Where the S&P 500 Goes in 2024
The stock market has rallied hard over the past few months, fueled by optimism over slowing inflation. The Fed, or FOMC, also recently signaled potential interest rate cuts in 2024, which poured gas


